StemCell Therapy

REHOVOT, Israel, July 15, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (Nasdaq: KMDA) (KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, announced today that the Company, the Employees’ Union of Kamada’s Beit Kama production facility in Israel, and the Histadrut - General Federation of Labor in Israel, signed a new collective agreement detailing the understandings reached between the parties. The agreement will be effective through the end of 2029, while certain economic terms may be renegotiated by the parties following the lapse of the first four years of the term of the agreement.

See the original post:
Kamada Announces Resolution to the Labor Strike at the Company’s Manufacturing Facility in Israel; A New, Eight-Year Collective Agreement Signed

This entry was posted on July 17, 2022 at 1:46 am and is filed under Global News Feed. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |